411 REFERENCE · Wikibooks
Radiation Oncology/RTOG Trials/9910
Reference material by Wikibooks contributors. This retains its source identity and is not 411 news reporting.
RTOG 99-10 (PROSTATE)
Title: A Phase III Trial to Evaluate The Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate Risk Prostate Cancer
Objective: To compare the efficacy of moderate-duration (28-week) neoadjuvant total androgen suppression and RT with short-duration (8-week) neoadjuvant total androgen suppression and RT as related to disease-specific survival.
Protocol:
Arm 1: TAS x 8 weeks followed by 70.2 Gy RT + concurrent TAS
Arm 2: TAS x 28 weeks followed by 70.2 Gy RT + concurrent TAS
Eligibility:
(cT1b-T4 and GS 2-6 and PSA 10-100) or
(cT1b-T4 and GS 7 and PSA <20) or
(T1b-T1c and GS 8-10 and PSA <20)
N0M0
Enrollment Target: 1540 patients
Activation: February 14, 2000
Closed: May 3, 2004